249 related articles for article (PubMed ID: 29395713)
1. Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015).
Pfaller MA; Flamm RK; Duncan LR; Streit JM; Castanheira M; Sader HS
Diagn Microbiol Infect Dis; 2018 May; 91(1):77-84. PubMed ID: 29395713
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
[TBL] [Abstract][Full Text] [Related]
3. Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study.
Rossolini GM; Dryden MS; Kozlov RS; Quintana A; Flamm RK; Läuffer JM; Lee E; Morrissey I; CLASS Study Group
J Antimicrob Chemother; 2011 Jan; 66(1):151-9. PubMed ID: 21051375
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
Pillar CM; Aranza MK; Shah D; Sahm DF
J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
[TBL] [Abstract][Full Text] [Related]
5. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial activity of ceftobiprole and comparator agents when tested against gram-positive and -negative organisms collected across China (2016-2018).
Dandan Y; Shi W; Yang Y; Yonggui Z; Zhu D; Yan G; Hu F
BMC Microbiol; 2022 Nov; 22(1):282. PubMed ID: 36435810
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial activity of ceftobiprole against gram-negative and gram-positive pathogens: results from INVITA-A-CEFTO Brazilian study.
Cereda RF; Azevedo HD; Girardello R; Xavier DE; Gales AC;
Braz J Infect Dis; 2011; 15(4):339-48. PubMed ID: 21861004
[TBL] [Abstract][Full Text] [Related]
8. Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017).
Pfaller MA; Flamm RK; Duncan LR; Shortridge D; Smart JI; Hamed KA; Mendes RE; Sader HS
Diagn Microbiol Infect Dis; 2019 Jul; 94(3):304-313. PubMed ID: 30808530
[TBL] [Abstract][Full Text] [Related]
9. Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011).
Pfaller MA; Flamm RK; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2014 Apr; 78(4):422-8. PubMed ID: 24445158
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
Sader HS; Flamm RK; Jones RN
Diagn Microbiol Infect Dis; 2013 May; 76(1):61-8. PubMed ID: 23535208
[TBL] [Abstract][Full Text] [Related]
11. Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016.
Pfaller MA; Flamm RK; Mendes RE; Streit JM; Smart JI; Hamed KA; Duncan LR; Sader HS
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373807
[TBL] [Abstract][Full Text] [Related]
12. Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010.
Farrell DJ; Flamm RK; Sader HS; Jones RN
Antimicrob Agents Chemother; 2014 Jul; 58(7):3882-8. PubMed ID: 24777091
[TBL] [Abstract][Full Text] [Related]
13. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
Jones ME
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
Vega S; Dowzicky MJ
Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.
Karlowsky JA; Adam HJ; Baxter MR; Lagacé-Wiens PR; Walkty AJ; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2013 Nov; 57(11):5600-11. PubMed ID: 23979759
[TBL] [Abstract][Full Text] [Related]
16. Ceftaroline activity tested against uncommonly isolated Gram-positive pathogens: report from the SENTRY Antimicrobial Surveillance Program (2008-2011).
Sader HS; Jones RN; Stilwell MG; Flamm RK
Int J Antimicrob Agents; 2014 Mar; 43(3):284-6. PubMed ID: 24342717
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015.
Zhanel GG; Baxter MR; Adam HJ; Sutcliffe J; Karlowsky JA
Diagn Microbiol Infect Dis; 2018 May; 91(1):55-62. PubMed ID: 29338931
[TBL] [Abstract][Full Text] [Related]
18. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
Farrell DJ; Sader HS; Flamm RK; Jones RN
Int J Antimicrob Agents; 2014 Jun; 43(6):533-9. PubMed ID: 24856078
[TBL] [Abstract][Full Text] [Related]
19. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study.
Walkty A; Adam HJ; Laverdière M; Karlowsky JA; Hoban DJ; Zhanel GG;
Diagn Microbiol Infect Dis; 2011 Mar; 69(3):348-55. PubMed ID: 21353964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
